The Pharma Data

AUGUST 3, 2021

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. This pipeline has the potential to deliver up to 15 medicines for approval by 2025. The antiparasitic medicine NEXGARD ® for dogs remained the best-selling product with net sales up 16.4

Development 52

Development Research Contract Manufacturing Sales 52

The Pharma Data

OCTOBER 29, 2021

Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA). Source link: [link].

Medicine 40

Medicine Marketing Contract Manufacturing Trials 40

Roots Analysis

FEBRUARY 15, 2022

ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. Given the fact that ADCs are highly potent cytotoxic molecules, the manufacturing of ADCs requires elaborate technical capabilities and highly potent chemical substances. Our Social Media Platform.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52

pharmaphorum

NOVEMBER 12, 2020

Earlier this year, UCB also bought a 47-acre UK R&D campus from Eli Lilly, saying it intends to develop it as a hub for R&D in “gene therapies, translational medicine and antibody discovery.”.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

The Pharma Data

MARCH 24, 2021

Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. Outlook 2021: slight year-on-year increase in net sales on a comparable basis. The company spent 3.7 The company invested 1.05 billion EUR (2019: 1.07

Sales 52

Sales Contract Manufacturing Medicine Antibody 52

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

The Pharma Data

MARCH 28, 2022

The Effisayil™ 1 trial, recently published in The New England Journal of Medicine , showed significant clearance of skin pustules in patients with GPP flares within the first week after treatment with a single intravenous dose of spesolimab versus placebo. of patients had no visible pustules after the 12-week trial duration and 81.3%

Dermatology 52

Dermatology Trials Contract Manufacturing Medicine 52

Roots Analysis

OCTOBER 24, 2023

Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

XTalks

APRIL 11, 2024

On the other hand, Abecma is now approved as a third-line treatment for patients with triple-class-exposed disease, which means previous treatment with an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody. Plasma cells help fight infections by producing antibodies.

FDA Approval 52

FDA Approval Manufacturing Trials Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 . mg and 2.0

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Evinacumab , an antibody to ANGPTL3.

Sales 40

Sales Production Manufacturing Antibody 40

The Pharma Data

JULY 29, 2021

Based on current projections, Pfizer and BioNTech expect to manufacture in total up to 3 billion doses by the end of December 2021, subject to continuous process improvements, expansion at current facilities and adding new suppliers and contract manufacturers. Total Oper. down 15%, despite 2% year-over-year growth in U.S.

Manufacturing 52

Manufacturing Sales Vaccination Vaccine 52

The Pharma Data

JULY 21, 2021

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

The Pharma Data

MAY 4, 2021

Internal Medicine. Biosimilars, which grew 79% operationally to $530 million, primarily driven by recent oncology monoclonal antibody biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) globally, as well as continued growth from Retacrit (epoetin) in the U.S.; First-Quarter. . 1,611. . *. *.

Vaccination 40

Vaccination Vaccine Production Sales 40

Pharmaceutical Technology

APRIL 24, 2023

These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. The recent pandemic has highlighted severe shortcomings with respect to the availability of contract manufacturing facilities,” says Bhalgat.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

Pharmaceutical Technology

MARCH 21, 2023

In such turbulent times, ensuring the most efficient and cost-effective manufacturing frameworks becomes even more important. Most pharmaceutical and biotech companies outsource certain production tasks to contract manufacturing organizations (CMOs).

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

Pharmaceutical Technology

JANUARY 15, 2023

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). Seagen has contracted the antibody drug conjugate’s (ADC) manufacturing to several companies.

Manufacturing 130

Manufacturing Packaging Packaging Contract Manufacturing 130

The Pharma Data

JUNE 24, 2021

The production capacity has consistently grown due to continued enhancements to the vaccine’s supply chain, which include expanding existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 27, 2023

Manufacturing a drug therapy usually involves several different stakeholders. The monoclonal antibody targeting IL-4 and IL-13 is approved in several chronic inflammatory conditions. The parenteral manufacturing and packaging for Dupixent are outsourced to Catalent. GlobalData is the parent company of Pharmaceutical Technology.

Manufacturing 130

Manufacturing Drugs Packaging Packaging 130